PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma | Zendy

Ajay K. Gopal | Zendy; Brad S. Kahl | Zendy; Sven de Vos | Zendy; Nina D. WagnerJohnston | Zendy; Stephen J. Schuster | Zendy; Wojciech Jurczak | Zendy; Ian W. Flinn | Zendy; Christopher R. Flowers | Zendy; Peter Martin | Zendy; Andreas Viardot | Zendy; Kristie A. Blum | Zendy; André Goy | Zendy; Andrew Davies | Zendy; Pier Luigi Zinzani | Zendy; Martin Dreyling | Zendy; Dave Johnson | Zendy; Langdon L. Miller | Zendy; Leanne Holes | Zendy; Daniel Li | Zendy; Roger Dansey | Zendy; Wayne R. Godfrey | Zendy; Gilles Salles | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

Author(s) -

Ajay K. Gopal,

Brad S. Kahl,

Sven de Vos,

Nina D. WagnerJohnston,

Stephen J. Schuster,

Wojciech Jurczak,

Ian W. Flinn,

Christopher R. Flowers,

Peter Martin,

Andreas Viardot,

Kristie A. Blum,

André Goy,

Andrew Davies,

Pier Luigi Zinzani,

Martin Dreyling,

Dave Johnson,

Langdon L. Miller,

Leanne Holes,

Daniel Li,

Roger Dansey,

Wayne R. Godfrey,

Gilles Salles

Publication year - 2014

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1314583

Subject(s) - idelalisib , pi3k/akt/mtor pathway , lymphoma , phosphatidylinositol , cancer research , kinase , medicine , chemistry , signal transduction , chronic lymphocytic leukemia , leukemia , ibrutinib , biochemistry

Phosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling and microenvironmental support signals that promote the growth and survival of malignant B lymphocytes. In a phase 1 study, idelalisib, an orally active selective PI3Kδ inhibitor, showed antitumor activity in patients with previously treated indolent non-Hodgkin's lymphomas.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research